Skip to main content
Equibles

ALPS ADVISORS INC

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1376113 Denver, CO
Back to ACAD Full portfolio

Position in ACAD

as of Jun 30, 2026 · filed Jul 29, 2026
Position Value
$4,985,339
+$1,360,966 QoQ
Shares Held
197,049
+21.0% QoQ
Ownership
0.114%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#74
of 354 holders
Holding Since
Jun 2021
21 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ACAD Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ALPS ADVISORS INC holds $213,436,831 across 115 Biotechnology names. ACAD ranks #10 (2.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RPRX
Royalty Pharma plc
 315,335 $17,680,833
2 APGE
Apogee Therapeutics, Inc.
 62,523 $8,298,677
3 CGON
CG Oncology, Inc.
 89,218 $6,338,938
4 XENE
Xenon Pharmaceuticals Inc.
 97,610 $5,891,739
5 ORKA
Oruka Therapeutics, Inc.
 61,014 $5,806,702
6 DNTH
Dianthus Therapeutics, Inc. /DE/
 55,281 $5,388,791
7 TVTX
Travere Therapeutics, Inc.
 93,981 $5,339,060
8 DFTX
Definium Therapeutics, Inc.
 110,388 $5,192,651

All Filings in ACAD

Export CSV
21 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $4,985,339 197,049
2026-03-31 $3,624,373 162,820
2025-12-31 $4,225,441 158,197
2025-09-30 $2,130,030 99,814
2025-06-30 $2,413,575 111,895
2025-03-31 $2,329,137 140,225
2024-12-31 $2,468,882 134,544
2024-09-30 $1,954,736 127,096
2024-06-30 $2,094,072 128,866
2024-03-31 $2,148,944 116,222
2023-12-31 $3,498,360 111,733
2023-09-30 $2,517,680 120,810
2023-06-30 $2,862,887 119,536
2023-03-31 $2,011,538 106,883
2022-12-31 $1,746,487 109,704
2022-09-30 $1,445,667 88,366
2022-06-30 $1,331,279 94,484
2022-03-31 $4,012,793 165,681
2021-12-31 $4,342,266 186,044
2021-09-30 $3,270,409 196,894
2021-06-30 $5,126,265 210,179